First patient treated in trial of Beacon Therapeutics’ XLRP treatment
The study is enrolling male participants aged between 12 and 50 years who have a confirmed XLRP diagnosis.
Cytiva Navigating cell therapy WP 4
Kenai doses first patient in Phase I trial of cell therapy for Parkinson’s
UK MHRA clears Ensoma’s EN-374 trial application for X-CGD
EpilepsyGTx secures $33m to progress FRE therapy through Phase I/IIa trials
Protara’s cell therapy touts BCG-naïve treatment potential in Phase II
Capricor stock soars after pivotal DMD cell therapy trial meets endpoints
Imugene announces Phase Ib azer-cel efficacy data
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
